Zacks: Brokerages Anticipate Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) to Post -$1.53 Earnings Per Share

Brokerages expect Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) to post earnings of ($1.53) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Madrigal Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.74) and the highest is ($1.33). Madrigal Pharmaceuticals posted earnings per share of ($0.75) during the same quarter last year, which would suggest a negative year over year growth rate of 104%. The business is scheduled to announce its next earnings report on Wednesday, February 26th.

According to Zacks, analysts expect that Madrigal Pharmaceuticals will report full year earnings of ($5.10) per share for the current fiscal year, with EPS estimates ranging from ($5.39) to ($4.44). For the next fiscal year, analysts expect that the company will report earnings of ($6.79) per share, with EPS estimates ranging from ($8.22) to ($5.22). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Madrigal Pharmaceuticals.

Several brokerages recently issued reports on MDGL. Svb Leerink restated an “outperform” rating on shares of Madrigal Pharmaceuticals in a research note on Thursday, January 2nd. BidaskClub upgraded Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Zacks Investment Research upgraded Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 15th. UBS Group upgraded Madrigal Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $125.00 to $127.00 in a research note on Thursday, January 9th. Finally, Citigroup reduced their price objective on Madrigal Pharmaceuticals from $173.00 to $166.00 and set a “buy” rating on the stock in a research note on Monday, December 2nd. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Madrigal Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $161.57.

MDGL traded up $0.46 during trading hours on Friday, hitting $90.23. 71,333 shares of the stock were exchanged, compared to its average volume of 161,378. The stock has a 50-day simple moving average of $86.38 and a 200-day simple moving average of $93.01. Madrigal Pharmaceuticals has a 12 month low of $74.05 and a 12 month high of $148.18. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -20.51 and a beta of 1.01.

In other Madrigal Pharmaceuticals news, major shareholder Bay City Capital Llc sold 1,200,000 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $105.47, for a total value of $126,564,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 47.69% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC grew its stake in Madrigal Pharmaceuticals by 90.3% during the 4th quarter. Cubist Systematic Strategies LLC now owns 13,497 shares of the biopharmaceutical company’s stock valued at $1,230,000 after acquiring an additional 6,404 shares in the last quarter. UBS Asset Management Americas Inc. lifted its holdings in shares of Madrigal Pharmaceuticals by 90.6% during the 4th quarter. UBS Asset Management Americas Inc. now owns 7,036 shares of the biopharmaceutical company’s stock valued at $641,000 after buying an additional 3,344 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Madrigal Pharmaceuticals by 5.2% during the 4th quarter. Bank of New York Mellon Corp now owns 34,174 shares of the biopharmaceutical company’s stock valued at $3,113,000 after buying an additional 1,679 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Madrigal Pharmaceuticals by 58.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 164,801 shares of the biopharmaceutical company’s stock valued at $15,015,000 after buying an additional 60,567 shares during the last quarter. Finally, Laurion Capital Management LP lifted its holdings in shares of Madrigal Pharmaceuticals by 3,158.9% during the 4th quarter. Laurion Capital Management LP now owns 135,797 shares of the biopharmaceutical company’s stock valued at $12,372,000 after buying an additional 131,630 shares during the last quarter. Institutional investors own 61.79% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.

Further Reading: What is a stock buyback?

Get a free copy of the Zacks research report on Madrigal Pharmaceuticals (MDGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.